What is GlycoNex’s GNX102 and which clinical stage has it reached?
GNX102 is GlycoNex’s humanized monoclonal antibody targeting tumor-associated glycan structures; its registered study NCT04250597 was Phase 1. [1]
The record last updated on May 6, 2024 lists the trial as TERMINATED and says the expansion phase was not performed following the sponsor’s business decision after the maximum tolerated dose was reached. [1]
GlycoNex’s current pipeline separately lists GNX1021 as a clinical-stage ADC, so its Phase 1 status should not be assigned to GNX102. [1]
Dated evidence
| Claim | Value | As of | Source and original quotation |
|---|---|---|---|
| Modality and target | Humanized monoclonal antibody targeting novel tumor glycan structures | 2024-05-06 | Primary sourceGNX102 is a humanized monoclonal antibod |
| Registered phase | NCT04250597; PHASE1 | 2024-05-06 | Primary sourcePHASE1 |
| Trial status | TERMINATED; last posted update 2024-05-06 | 2024-05-06 | Primary sourceTERMINATED |
| Reason stopped | Maximum tolerated dose reached; expansion not performed per sponsor business decision | 2024-05-06 | Primary sourceMaximum tolerated dose reached |
| Separate ADC program | GNX1021; Phase 1 | 2026-10-22 | Primary sourceclinical-stage GNX1021 |
Not disclosed in the public documents
The checked GNX102 registry record does not disclose a restart date; GNX1021’s separate ADC progress is not evidence of a restarted GNX102 trial. Document reviewed 2026-10-22
GNX102